當(dāng)前位置: 首頁 - 產(chǎn)品目錄 - 小分子抑制劑
Fingolimod,hydrochloride ( FTY720 , FTY-720A,Gilenia?,Gilenya?) 鹽酸芬戈莫德
貨號 | ICG2051 | 售價(元) | 1325 |
規(guī)格 | 100mg | CAS號 | 162359-56-0 |
- 產(chǎn)品簡介
- 相關(guān)產(chǎn)品
貨號
名稱
規(guī)格
價格
ICG2051-0100MG
Fingolimod,hydrochloride
100MG
1325
ICG2051-0200MG
Fingolimod,hydrochloride
200MG
2408
ICG2051-0500MG
Fingolimod,hydrochloride
500MG
4816
ICG2051-1000MG
Fingolimod,hydrochloride
1G
7224
產(chǎn)品簡介:
芬戈莫德(FTY720)是一種免疫抑制劑,通常用于治療多發(fā)性硬化癥,也有抗癌作用,可以作為HDACi(組蛋白脫乙酰酶抑制劑)[1]。
在體外,在7.5或10μM時,芬戈莫德誘導(dǎo)D283和DAOY培養(yǎng)物中的細(xì)胞活力明顯下降,還導(dǎo)致乙?;疕3的水平明顯增加[1]。在體外,Fingolimod對雄性激素依賴性和非依賴性前列腺癌細(xì)胞顯示出細(xì)胞毒性抗增殖作用,IC50范圍為3.0±0.3至6.8±1.7 μM[2]。Jurkat T淋巴細(xì)胞接觸Fingolimod后,以時間和濃度依賴的方式抑制延遲整流K+ 電流(IK(DR))的振幅,IC50值為1.51 μM[3]。Fingolimod降低了Ph(+)和Ph(-)ALL細(xì)胞系和患者樣本的增殖和生存能力,其生存能力的IC50值在5.3至7.9 μM之間[4] 。Fingolimod對OSCC細(xì)胞系SCC4、SCC25和SCC2095的生存能力有不同程度的抑制,IC50值分別為6.1、6.3和4.5 μM[5]。
體內(nèi)試驗表明,E13 C57BL/6野生型小鼠在照射4周后,用1 mg/kg的劑量處理,可明顯提高DG(齒狀回)和SVZ(室下區(qū))中DCX+神經(jīng)元的存活率,同時增殖細(xì)胞也有輕微增加[6]。在體內(nèi),5xFAD小鼠接受1 mg/kg/day的芬戈莫德治療后,外周血淋巴細(xì)胞計數(shù)和大腦Aβ 水平均下降,但接受0.03 mg/kg/day的治療后,記憶力得到改善,大腦小膠質(zhì)細(xì)胞和星形膠質(zhì)細(xì)胞的激活減少,海馬的GABA和甘油磷酸膽堿水平恢復(fù),對循環(huán)淋巴細(xì)胞計數(shù)沒有影響[7]。在體內(nèi),C57BL/6JOlaHsd小鼠接受0.5 mg/kg芬戈莫德治療后,病變大小(中風(fēng))增加,但同側(cè)腦萎縮減少,對行為結(jié)果沒有影響[8]。
產(chǎn)品性質(zhì):
Cas No.:162359-56-0
別名:鹽酸芬戈莫德; FTY720
化學(xué)名:2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol;hydrochloride
Canonical SMILES:CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
分子式:C19H34ClNO2
分子量:343.94
溶解度:DMSO : ≥ 100 mg/mL; Water : 50 mg/mL
儲存條件:Store at -20°C
注意事項:
為了您的安全和健康,請穿實驗服并戴一次性手套操作。
References:
[1] Perla AS, et al. Fingolimod (Fingolimod) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells. Pediatr Hematol Oncol. 2020 Mar;37(2):170-175.
[2] Allam RM, et al. Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol Lett. 2018 Jul;291:77-85.
[3] Chang WT, et al. Actions of Fingolimod (Fingolimod), a Sphingosine-1-Phosphate Receptor Modulator, on Delayed-Rectifier K+ Current and Intermediate-Conductance Ca2+-Activated K+ Channel in Jurkat T-Lymphocytes. Molecules. 2020 Oct 2;25(19):4525.
[4] Wallington-Beddoe CT, et al. Fingolimod produces caspase-independent cell death of acute lymphoblastic leukemia cells. Autophagy. 2011 Jul;7(7):707-15.
[5] Bai LY, et al. Fingolimod Induces Autophagy-Associated Apoptosis in Human Oral Squamous Carcinoma Cells, in Part, through a Reactive Oxygen Species/Mcl-1-Dependent Mechanism. Sci Rep. 2017 Jul 17;7(1):5600.
[6] Metzdorf J, et al. Fingolimod for Irradiation-Induced Neurodegeneration. Front Neurosci. 2019 Jul 9;13:699.
[7] Carreras I, et al. Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. Sci Rep. 2019 Jul 29;9(1):10972.
[8] Diaz Diaz AC, et al. Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities. Front Pharmacol. 2022 Jul 13;13:920449.